ACTT-1
In hospitalised adult patients with evidence of lower respiratory tract infection due to COVID-19, is remdesivir superior to placebo in shortening the time to recovery?
Continue reading »A compendium of critical appraisals in Intensive Care Medicine research and related specialties
In hospitalised adult patients with evidence of lower respiratory tract infection due to COVID-19, is remdesivir superior to placebo in shortening the time to recovery?
Continue reading »In patients with severe sepsis what is the sensitivity of blood cultures taken after the initiation of antimicrobial therapy?
Continue reading »In patients older than 65-years with vasodilatory hypotension receiving vasopressors, does a target mean arterial pressure (MAP) of 60-65mmHg compared with usual care impact mortality?
Continue reading »Does treatment with vitamin C, hydrocortisone, and thiamine lead to a more rapid resolution of septic shock compared with hydrocortisone alone?
Continue reading »Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial Fowler AA. JAMA; 2019;322(13):1261-1270 Clinical Question In patients with sepsis and acute respiratory distress syndrome, can intravenous administration of vitamin C, compared to placebo, reduce organ failure scores and biomarkers of inflammation and vascular injury? […]
Continue reading »In adult patients with sepsis-associated coagulopathy does the administration of human recombinant thrombomodulin (rhsTM) compared to placebo reduce 28 day mortality?
Continue reading »In patients with septic shock, does the administration of thiamine lead to more rapid lactate clearance and improved clinical outcomes?
Continue reading »In patients with septic shock, does early low-dose norepinephrine compared with standard care increase shock control at six hours?
Continue reading »Do one or more doses of levocarnitine reduce organ failure in septic shock at 48 hours, compared with placebo?
Continue reading »In adult patients with septic shock and high circulating endotoxin activity, does the use of polymyxin B haemoperfusion therapy significantly decrease 28-day mortality?
Continue reading »